# Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients

> **NCT05349968** · PHASE1 · COMPLETED · sponsor: **Shanxi Kangbao Biological Product Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lipovirtide for injection

## Key facts

- **NCT ID:** NCT05349968
- **Lead sponsor:** Shanxi Kangbao Biological Product Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-10
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349968, "Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT05349968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*